Matthew Burke on Potential Challenges Facing Nurses in the Field of Immunotherapy

The median progression-free survival with atezolizumab to cabozantinib was 10.6 vs 10.8 months with cabozantinib alone.

Lindsay Diamond, MSN, AGNP-C, AOCNP, discusses findings from CheckMate 274 and other data presented during the 2023 ASCO Genitourinary Cancers Symposium.

Tremelimumab plus durvalumab (STRIDE) showed a manageable immune-related adverse event profile in the phase 3 HIMALAYA trial.

In this episode of “The Vitals,” Mark Honor, PA-C, discusses adverse event management in patients receiving different therapeutic options.

Combined adjuvant treatment with mRNA-4157 in combination with pembrolizumab improved recurrence rates in patients with resected high-risk melanoma.

Patients who received pembrolizumab plus cisplatin and gemcitabine achieved a median overall survival of 12.7 months, compared with 10.9 months with cisplatin and gemcitabine alone.